NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge.
about
Invariant NKT cells as novel targets for immunotherapy in solid tumorsThe role of NKT cells in tumor immunityHow do natural killer T cells help B cells?Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agentsThe regulatory role of invariant NKT cells in tumor immunityA New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR EffectActivation of invariant NKT cells exacerbates experimental visceral leishmaniasisCombined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.Invariant NKT cells sustain specific B cell responses and memory.PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cellsSublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge.Stimulation of natural killer T cells by glycolipidsICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival.Lipid and glycolipid antigens of CD1d-restricted natural killer T cells.NKG2A inhibits invariant NKT cell activation in hepatic injury.PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS.Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodiesKLRG+ invariant natural killer T cells are long-lived effectors.Nonconventional CD8+ T cell responses to Listeria infection in mice lacking MHC class Ia and H2-M3.Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant.A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infectionTargeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma modelCD1d-dependent expansion of NKT follicular helper cells in vivo and in vitro is a product of cellular proliferation and differentiationThe Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their ProductsInfluence of In Vitro IL-2 or IL-15 Alone or in Combination with Hsp 70 Derived 14-Mer Peptide (TKD) on the Expression of NK Cell Activatory and Inhibitory Receptors on Peripheral Blood T Cells, B Cells and NKT CellsTLR4, 5, and 9 Agonists Inhibit Murine Airway Invariant Natural Killer T Cells in an IL-12-Dependent Manner.Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humansSustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvantsThe role of invariant natural killer T cells in lupus and atherogenesisImpact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice.Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.NKT cell costimulation: experimental progress and therapeutic promiseInvariant natural killer T cells: bridging innate and adaptive immunity.Natural killer T cells in health and disease.Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population.CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells.Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells
P2860
Q21284987-78629F1A-5C24-4814-8498-0051E80BD192Q24648939-AB2ACB55-0A98-4F44-8BC7-64ABFE86A7C2Q24650966-11FA4BEE-C8B3-4920-837A-5B5DC5D9D61AQ26748456-3EBCDB75-BD41-4532-86E3-BF0F28855F15Q27023425-235B86CC-1880-462F-8C4D-3F4D66FA978DQ27300754-3CD9A879-377A-439D-9109-1B6698641BF9Q27318814-7E2D7E34-E91D-4FA9-9390-BEEB1EAAA60FQ30374900-EC44A225-13E8-4334-B7C0-EB1F61FD6F4FQ30479030-78C261B0-62C6-4530-A5C8-F048CF3A2CF0Q30488777-42D723EE-CCF5-4D84-83DD-8C02D57C9B6CQ31153121-6117E3F1-5CAB-42E7-AB45-7E127F9E880DQ33599059-AD7B1D9C-E800-4874-84EC-7358C71FBBC9Q33715268-7C0E32D1-3DAE-4DC8-B8B9-E0E17C490760Q33724575-F6FBB37B-7533-403F-A8CE-E9D7773548DEQ33739557-5C4A53D7-FCE7-4486-8ADC-5BA6AE08BC66Q33753894-5D4A79F2-1011-4DB6-BF6B-ECF622D48F09Q33988381-71BB3585-EEA1-479E-A25E-B6200F56BB84Q34043615-99A66B1B-AC1B-40E6-8D27-5A53264B6C4BQ34120251-0ED50165-907D-4259-9FDE-86168D78B4B2Q34748695-3D09F80F-65A6-405C-9310-51F1C4CD811FQ34781602-9ED5EA5D-BA24-432E-85E5-88497FE7F80CQ35015787-8CBA103B-8AFD-478C-9936-0EA042014B5DQ35516545-3F9D26D2-3EEC-4AB3-BEBB-ED2A665A02AFQ35524113-030F709B-B4E7-4ECF-9DB2-10DC511F5397Q35600087-8D318791-8240-4C77-AE24-D85BEA7F56A7Q35959395-7A923DC1-A7A6-47D8-872E-779EA2412EF5Q36177350-5E399451-34B1-4B42-8F94-E016A04219A2Q36239694-2AD4B230-E03E-4A96-A4D1-BB6A04E743A9Q36439026-24A409BF-DB18-48BA-85A5-570C9160C162Q36474450-B0641292-802F-4DA6-97D7-D697139A68A7Q36487076-A2FAD4B5-329A-41DA-936D-3C0B0C59A5EAQ36597496-E2C4F472-E5C2-44CF-88FE-29CDD2E3F48BQ36598607-D15F4434-7C79-4BE8-9C15-AD2E72F84029Q36739843-0E847796-051A-4F5E-B96A-0C3200EC9700Q36739848-2453A6B6-7E7B-4D9C-8447-7A0645C0554FQ36765720-5DE32EA7-CD07-4CC3-9804-432C2CE7CAA6Q36837547-B825CD1D-4FB7-4A65-8D5D-FFA8A5F42BD4Q36951719-8E482FAE-7041-4E37-93C9-FCD56FBBA921Q37051132-E92F4C3A-EB7A-4ED1-BDD0-F5AD72426BDEQ37083610-FBD374D5-0A5B-4675-981C-3C59F528B2A1
P2860
NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
NKT cell stimulation with glyc ...... o further antigenic challenge.
@ast
NKT cell stimulation with glyc ...... o further antigenic challenge.
@en
NKT cell stimulation with glyc ...... o further antigenic challenge.
@nl
type
label
NKT cell stimulation with glyc ...... o further antigenic challenge.
@ast
NKT cell stimulation with glyc ...... o further antigenic challenge.
@en
NKT cell stimulation with glyc ...... o further antigenic challenge.
@nl
prefLabel
NKT cell stimulation with glyc ...... o further antigenic challenge.
@ast
NKT cell stimulation with glyc ...... o further antigenic challenge.
@en
NKT cell stimulation with glyc ...... o further antigenic challenge.
@nl
P2093
P2860
P50
P1476
NKT cell stimulation with glyc ...... o further antigenic challenge.
@en
P2093
Adam P Uldrich
Daniel G Pellicci
Konstantinos Kyparissoudis
Nadine Y Crowe
P2860
P304
P356
10.4049/JIMMUNOL.175.5.3092
P407
P577
2005-09-01T00:00:00Z